Antigen News and Research

RSS

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Up to one million people -- mainly pregnant woman and young children -- are killed each year by the Plasmodium falciparum parasite, which causes the most devastating form of human malaria.

26 Feb 2015

Virginia Tech biochemists identify potential drug target against sleeping sickness

Virginia Tech biochemists are trying to deliver a stern wake-up call to the parasite that causes sleeping sickness.

24 Feb 2015

New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

A new Duke-NUS-led study has identified a super-potent antibody which requires a minute amount to neutralize the dengue virus.

21 Feb 2015

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells.

20 Feb 2015

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

20 Feb 2015

IDRI Announces $4M BARDA Cooperative Agreement To Establish Adjuvant Hub

The international outbreak of Ebola in 2014 serves as a reminder for the need to be proactive in preparing for the rapid spread of any newly emerging or re-emerging infectious disease. IDRI today announces it has received $4 million in funding from the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, to develop an adjuvant manufacturing hub with both preclinical and clinical expertise to facilitate pandemic influenza preparedness in developing countries.

19 Feb 2015

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research.

19 Feb 2015

NIAID expands Tuberculosis Research Units program to drive innovation in TB research

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is expanding its Tuberculosis Research Units program in an effort to drive innovation in tuberculosis (TB) research. NIAID is awarding up to $15.2 million in fiscal year 2015 and as much as $105.3 million over seven years to fund four institutions that will act as a collaborative TBRU network.

19 Feb 2015

IL-23 predicts PegIFN response in chronic HBV

High baseline serum levels of interleukin-23 can help to identify hepatitis B e antigen-positive chronic hepatitis B patients who are likely to respond to pegylated interferon treatment, a Chinese study indicates.

18 Feb 2015

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Researchers from the Republic of Korea have found that the efficacy of tenofovir disoproxil fumarate monotherapy is comparable to that of TDF plus entecavir in chronic hepatitis B patients with genotypic resistance to entecavir.

18 Feb 2015

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term tenofovir disoproxil fumarate therapy is effective in Chinese patients with chronic hepatitis B virus infection who have relapsed after treatment with multiple nucleos(t)ide analogues, research suggests.

18 Feb 2015

UT Southwestern scientists identify new biomarker that could optimize chemotherapy response

UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.

18 Feb 2015

Transplantation conditioning choices impact on CML outcomes revealed

For chronic myeloid leukaemia patients in their first chronic phase, the optimal pretransplantation conditioning regimen may be cyclophosphamide combined with intravenous busulfan, research suggests.

17 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

Findings show how human bodies restrict production of IgE to prevent allergic reaction

Scientists from the CNRS, INSERM and Université de Limoges, working in the Laboratoire Contrôle de la Réponse Immune B et Lymphoproliférations (CNRS/Université de Limoges) have demonstrated that the production of type E immunoglobulins (IgE) by B lymphocytes induces a loss in their mobility and the initiation of cell death mechanisms.

16 Feb 2015

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, presented data demonstrating that obiltoxaximab (ETI-204) demonstrated a statistically significant survival benefit across a range of disease severity in animal model studies assessing treatment of inhalational anthrax, as well as effectiveness in post-exposure prophylaxis.

13 Feb 2015

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

GenomeDx Biosciences today announced the publication of a positive validation study for the Decipher® Prostate Cancer Classifier, a genomic test for prostate cancer. The study, published in the Journal of Clinical Oncology, showed that patients with low genomic risk (as determined by Decipher) may be optimally managed with observation after radical prostatectomy (prostate surgery), while those with high genomic risk (as determined by Decipher) may be better managed earlier with adjuvant radiotherapy.

10 Feb 2015

New AGA guideline provides guidance to prevent HBV reactivation

Long-term immunosuppressive therapy can cause the hepatitis B virus (HBV) to become active, even in patients who are not aware that they are infected with the virus. A new guideline from the American Gastroenterological Association provides guidance to physicians and patients who use immunosuppressive agents for the treatment of a variety of disorders, including gastrointestinal, dermatologic, neurologic and rheumatologic, among others.

9 Feb 2015

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases.

6 Feb 2015

Antigen News and Research

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

Researchers reveal how malaria parasite deploys genetic trickery to escape immune system attack

Virginia Tech biochemists identify potential drug target against sleeping sickness

New Duke-NUS-led study identifies super-potent antibody that can neutralize dengue virus

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Research findings lay groundwork for improving treatment assessment for men with prostate cancer

IDRI Announces $4M BARDA Cooperative Agreement To Establish Adjuvant Hub

Study results pave way for new clinical trial for glioblastoma patients

NIAID expands Tuberculosis Research Units program to drive innovation in TB research

IL-23 predicts PegIFN response in chronic HBV

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

UT Southwestern scientists identify new biomarker that could optimize chemotherapy response

Transplantation conditioning choices impact on CML outcomes revealed

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Findings show how human bodies restrict production of IgE to prevent allergic reaction

Elusys presents positive results of obiltoxaximab for treating inhalational anthrax, post-exposure prophylaxis

GenomeDx announces publication of positive validation study for Decipher Prostate Cancer Classifier

New AGA guideline provides guidance to prevent HBV reactivation

Chemotherapy or immunosuppressive treatment may reactivate HBV

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Sensing a Healthier Future

Latest Life Science News